Pitavastatina como estatina de escolha para o controle da dislipidemia em pacientes infectados pelo HIV em uso de antirretrovirais
DOI:
https://doi.org/10.56102/afmo.2023.279Palavras-chave:
Antirretrovirais, HIV, Hiperlipidemia, Hipolipemiantes, EstatinasResumo
Objetivo: explicar o porquê da pitavastatina ser o hipolipemiante de escolha para controle lipídico e redução do risco cardiovascular em pessoas
infectadas pelo HIV. Métodos: Realização de buscas na PubMed e na Biblioteca Virtual em Saúde (BVS), com uso destes descritores, em inglês e português: “Pitavastatina”, “HIV”, “Estatinas”, “Infectados pelo HIV”, “Dislipidemia” e “Antirretrovirais”. Foram recuperados 46 artigos, reduzidos, após o refinamento, a 9, sendo 6 da PubMed e 3 da BVS. Resultados: O uso de antirretrovirais (ARV) aumenta significativamente as alterações lipídicas em pessoas infectadas pelo HIV, devendo ser associado à terapia hipolipemiante com as estatinas. Mas, como a maioria é metabolizada pelo sistema do citocromo P450 3A4, inibido por alguns ARV, destaca-se
a pitavastatina, visto que seu processo de metabolização ocorre, primariamente, por glucoronidação. Além disso, comprovou-se que esta estatina reduziu mais significativamente os marcadores inflamatórios e os níveis do LDL-c, do que a pravastatina, cuja metabolização é através do mesmo mecanismo. Conclusão: Portanto, a pitavastatina é, preferencialmente, o hipolipemiante para corrigir a dislipidemia em pacientes infectados pelo HIV, devido às suas mínimas interações medicamentosas e maior redução lipídica e dos marcadores inflamatórios. Conclusão: A pitavastatina é, preferencialmente, o hipolipemiante para corrigir a dislipidemia em pacientes infectados pelo HIV, devido às suas mínimas interações medicamentosas e maior redução lipídica e dos marcadores inflamatórios.
Referências
Hoffman U, Lu MT, Olalere D, Adami EC, Osborne MT, Ivanov A, et al. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019 Jun; 212: 1-12. https://doi.org/10.1016/j.ahj.2019.02.011.
Hussain SK, Golozar A, Widney DP, Rappocciolo G, Penugonda S, Bream JH, et al. Effect of Statin Use on Inflammation and Immune Activation Biomarkers in HIV-Infected Persons on Effective Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2021 May; 37(5): 357-367. https://doi.org/10.1089/AID.2020.0127.
Wongprikorn A, Sukasem C, Puangpetch A, Numthavej P, Thakkinstian A, Kiertiburanakul S. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study. PLoS One. 2016 Jun 15;11(6):e0157531. https://doi.org/10.1371/journal.pone.0157531.
Gebhardt A, Fichtenbaum CJ. Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. Expert Opin Pharmacother. 2019 Oct;20(14):1719-1729. https://doi.org/10.1080/14656566.2019.1636033.
Fitch KV, Fulda ES, Grinspoon SK. Statins for primary cardiovascular disease prevention among people with HIV: emergent directions. Curr Opin HIV AIDS. 2022 Sep 1;17(5):293-300. https://doi.org/10.1097/COH.0000000000000752.
Toribio M, Fitch KV, Sanchez L, Burdo TH, Williams KC, Sponseller CA, et al. Effects of pitavastatinand pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017 Mar 27;31(6):797-806. https://doi.org/10.1097/QAD.0000000000001427.
Levy ME, Greenberg AE, Magnus M, Younes N, Castel A. Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients. AIDS Patient Care STDS. 2018 Feb;32(2):58-69. https://doi.org/10.1089/apc.2017.0304.
Bhan PAP, Ma Y, Scherzer R, Deeks SG, Hsue PY. Association between statin use, atherosclerosis, and mortality in HIV-infected adults. PLoS One. 2020; 15(4). https://doi.org/10.1371/journal.pone.0232636.
Pawlos A, Broncel M, Wlazłowska E, Jabłonowska E, Gorzelak-Pabiś P. Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations. PLoS One 2020; 15(12): e0244675. https://doi.org/10.1371/journal. pone.0244675.
Lee D. HIV: how to manage dyslipidaemia in HIV. Drugs Context. 2022; 11:2021-8-7. https://doi.org/10.7573/dic.2021-8-7.
Henning RJ, Greene JN. The epidemiology, mechanisms, diagnosis and treatment of cardiovascular disease in adult patients with HIV. Am J Cardiovasc Dis. 2023 Apr 15;13(2):101-121.
Fahme SA, Bloomfield GS, Peck R. Hypertension in HIV-Infected Adults: Novel Pathophysiologic Mechanisms. Hypertension. 2018 Jul;72(1):44-55. https://doi.org/10.1161/HYPERTENSIONAHA.118.10893.
Joshi PH, Miller PE, Martin SS, Jones SR, Massaro JM, D’Agostino RB Sr, et al. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients. AIDS. 2017 Apr 24; 31(7): 965-971. https://doi.org/10.1097/QAD.0000000000001423.
Mosepele M, Molefe-Baikai JO, Grinspoon SK, Triant VA. Benefits and risks of statin therapy in the HIV infected population. Curr Infect Dis Rep 2019; 20(8): 20. https://doi.org/10.1007/s11908-018-0628-7.
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532–61. https://doi.org/10.1016/S0140-6736(16)31357-5.
deFillipi C, Toribio M, Wong LP, Sadreyev R, Grundberg I, Fitch KV. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. J Infect Dis 2020 Sep 15; 222(6): 929-939. https://doi.org/10.1093/infdis/jiaa196.
Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017 Jul;4(7):e284-e294. https://doi.org/10.1016/S2352-3018(17)30075-9.
Toribio M, Fitch KV, Stone L, Zanni MV, Lo J, Filippi C, et al. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine 2018 Sep; 35: 58-66. https://doi.org/10.1016/j.ebiom.2018.08.039.
deFilippi C, Lo J, Christenson R, Grundberg I, Stone L, Zanni MV, et al. Novel mediators of statin effects on plaque in HIV: a proteomics approach. AIDS. 2018 Apr 24; 32(7): 867-876. https://doi.org/10.1097/QAD.0000000000001762.
Lee D. HIV: how to manage dyslipidemia in HIV. Drugs Context 2022; 11: 2021-8-7. https://doi.org/10.7573/dic.2021-8-7.
Bednasz C, Zingman BS, Luque AE, Fischl MA, Gripshover BM, Venuto CS, et al. Lipid-lowering therapy in HIV-infected patients: relationship with antiretroviral agents and impact of substance-related disorders. Curr Vasc Pharmacol 2016; 14(3): 280–287. https://doi.org/10.2174/1570161114666160106151652.
Sekhar RV. Treatment of dyslipidemia in HIV. Curr Atheroscler Rep. 2015 Apr;17(4):493. https://doi.org/10.1007/s11883-015-0493-x.
Myerson M, Malvestutto C, Aberg JA. Management of lipid disorders in patients living with HIV. J Clin Pharmacol. 2015; 55(9):957–974. https://doi.org/10.1002/jcph.473.
Courlet P, Livio F, Saldanha SA, Scherrer A, Battegay M, Cavassini M, et al. Real-life management of drug–drug interactions between antiretrovirals and statins. J Antimicrob Chemother 2020; 75: 1972–1980 https://doi.org/10.1093/jac/dkaa099.
Custodio JM, West S, SenGupta D, Zari A, Humeniuk R, Ling KHJ, et al. Evaluation of the Drug-Drug Interaction (DDI) Potential Between Cobicistat-Boosted Protease Inhibitors and Statins. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, Chicago, IL, USA, 2017.
Boettiger DC, Newall AT, Chattranukulchai P, Chaiwarith R, Khusuwan S, Avihingsanon A, et al. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. J Int AIDS Soc. 2020 Jun;23 Suppl 1(Suppl 1):e25494. https://doi.org/10.1002/jia2.25494.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2023 Thiago José Monteiro Borges da Silva Valente
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Esta licença permite que outros distribuam, remixem, adaptem e desenvolvam seu trabalho, mesmo comercialmente, desde que creditem a revista pela criação original.
